On October 31, 2022, NuChem Sciences, a Montréal-based contract research organization and leader in drug discovery, announced its acquisition of IniXium. This acquisition will allow NuChem to broaden its expertise in biological targets, also known as target proteins, whose manufacturing and understanding of their 3D structure are essential steps in the creation of new drugs.
IniXium is a Laval-based biotech company that offers expert services in recombinant protein production, biophysical characterization, protein crystallography, fragment screening and biologics and biosimilars.
Osler, Hoskin & Harcourt LLP advised IniXium with a team consisting of Nathalie Beauregard (Emerging and High Growth Companies), Samuel Cantin, Vincent Legault (Corporate), Alain Fournier, Evan Belfer (Tax) and Jeremy Perron (Employment and Labour).